Merck to take legal action against unauthorised distributors of its COVID treatment in China
Merck added that Sinopharm is the only legally authorised distributor of Merck's COVID-19 anti-viral molnupiravir in China
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Ridgeback Biotherapeutics
Merck allocates three million courses of Molnupiravir to be provided in first half of 2022 for use…
Merck is developing Molnupiravir in collaboration with Ridgeback Biotherapeutics and it has been authorised for use in more than…
UK government to purchase additional 1.75 million courses of Molnupiravir
With this additional procurement agreement, which follows a previously announced agreement for 480,000 courses of treatment, the…
Merck and Ridgeback seek Emergency Use Authorisation from US FDA for Molnupiravir
If authorised, Molnupiravir could be the first oral anti-viral medicine for the treatment of COVID-19